메뉴 건너뛰기




Volumn 368, Issue 20, 2013, Pages 1931-1932

HCV treatment - No more room for interferonologists?

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR;

EID: 84877731714     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1303818     Document Type: Editorial
Times cited : (32)

References (7)
  • 1
    • 79959381354 scopus 로고    scopus 로고
    • Telaprevir for retreatment of HCV infection
    • Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
    • (2011) N Engl J Med , vol.364 , pp. 2417-2428
    • Zeuzem, S.1    Andreone, P.2    Pol, S.3
  • 2
    • 79953176289 scopus 로고    scopus 로고
    • Boceprevir for previously treated chronic HCV genotype 1 infection
    • Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
    • (2011) N Engl J Med , vol.364 , pp. 1207-1217
    • Bacon, B.R.1    Gordon, S.C.2    Lawitz, E.3
  • 3
    • 84877739274 scopus 로고    scopus 로고
    • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
    • Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77.
    • (2013) N Engl J Med , vol.368 , pp. 1867-1877
    • Jacobson, I.M.1    Gordon, S.C.2    Kowdley, K.V.3
  • 4
    • 84877730954 scopus 로고    scopus 로고
    • Sofosbuvir for previously untreated chronic hepatitis C infection
    • Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
    • (2013) N Engl J Med , vol.368 , pp. 1878-1887
    • Lawitz, E.1    Mangia, A.2    Wyles, D.3
  • 5
    • 77957913871 scopus 로고    scopus 로고
    • Discovery of a β-d-2′-deoxy-2′-α-fluoro-2′- β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus
    • Sofia MJ, Bao D, Chang W, et al. Discovery of a β-d-2′-deoxy- 2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010;53:7202-18.
    • (2010) J Med Chem , vol.53 , pp. 7202-7218
    • Sofia, M.J.1    Bao, D.2    Chang, W.3
  • 6
    • 84871814966 scopus 로고    scopus 로고
    • Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C
    • Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44.
    • (2013) N Engl J Med , vol.368 , pp. 34-44
    • Gane, E.J.1    Stedman, C.A.2    Hyland, R.H.3
  • 7
    • 84877782905 scopus 로고    scopus 로고
    • Earlier sustained virologic response endpoints for regulatory approval and dose selection of hepatitis C therapies
    • March 4 (Epub ahead of print)
    • Chen J, Florian J, Carter W, et al. Earlier sustained virologic response endpoints for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013 March 4 (Epub ahead of print).
    • (2013) Gastroenterology
    • Chen, J.1    Florian, J.2    Carter, W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.